Michel Detheux is a seasoned biotech executive: Michel is the co-founder of iTeos and has served as Chief Executive Officer since its inception in 2011. He has been the driving force behind the capital increases of €4,4M and a series of national and European non-dilutive grants of €11M. In December 2014, Michel finalized a major deal with Pfizer for a strategic alliance to discover and develop cancer immunotherapies. In 2016, iTeos is a biotech company with 40 collaborators dedicated to the discovery of therapeutics targeting the immune tumor micro-environment.
His earlier experience includes founding and managing Euroscreen FAST, a business unit of Euroscreen SA, dedicated to worldwide biotech and pharma in vitro testing of drug candidates, which grew from 2 to 12 people with revenues increase by 5-fold in 3 years. Michel also extended his business development and management skills by developing R&D activities and partnerships for new drug discovery programs in various therapeutic s. During this period, he managed a sizeable, multidisciplinary team for 8 years and was involved in completion of several strategic alliances with pharmaceutical companies, including Cephalon, Novartis and Medarex.
Michel has a substantial international network in the biotech and pharma sectors and has authored 50 peer-reviewed scientific publications and is inventor of 27 patent applications.
Passionate about bridging science and business, Michel holds a degree in bioengineering, a PhD in Biochemistry from the Catholic University of Louvain and a Certificate in Business from Solvay Business School.